CLINICAL TRIALS PROFILE FOR TRESIBA
✉ Email this page to a colleague
All Clinical Trials for Tresiba
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01984372 ↗ | Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba® | Completed | Novo Nordisk A/S | 2013-11-06 | This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin therapy under normal clinical practice conditions. A total of 4000 patients will be enrolled to investigate long term (3 years of treatment) safety of Tresiba® and additional 2000 patients will be enrolled to assess the safety in an early stage of the PMS more precisely. At the time of enrolment the patients will be randomly allocated to either 3 years or 6 months observation group. | |
| NCT02117622 ↗ | A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India | Completed | Novo Nordisk A/S | 2015-07-24 | This study is conducted in Asia. The aim of the study is to evaluate long term safety and efficacy of Tresiba® (insulin degludec) in patients with diabetes mellitus in routine clinical practice in India. | |
| NCT02192450 ↗ | Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia | Completed | Aarhus University Hospital | Phase 4 | 2015-01-01 | The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia. |
| NCT02192450 ↗ | Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia | Completed | Copenhagen University Hospital, Denmark | Phase 4 | 2015-01-01 | The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia. |
| NCT02192450 ↗ | Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia | Completed | Hvidovre University Hospital | Phase 4 | 2015-01-01 | The purpose of this study is to determine whether insulin degludec compared to insulin glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the greatest potential benefit from optimised insulin treatment, which are patients with type 1 diabetes and high risk of nocturnal severe hypoglycaemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tresiba
Condition Name
Clinical Trial Locations for Tresiba
Trials by Country
Clinical Trial Progress for Tresiba
Clinical Trial Phase
Clinical Trial Sponsors for Tresiba
Sponsor Name
